Faruqi & Faruqi, LLP, a national securities law firm, announced an investigation into potential legal claims against Replimune Group, Inc. (NASDAQ: REPL). The firm is acting on behalf of investors who experienced financial losses. A federal securities class action lawsuit has been filed against the company.
The investigation centers on allegations of false and misleading statements made by Replimune and its executives. Specifically, the complaint alleges that the company overstated the prospects of the IGNYTE trial, a key clinical trial for its drug candidate. The FDA ultimately deemed the trial inadequate, leading to a significant market reaction.
The issue came to light when Replimune received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec). The CRL indicated that the FDA could not approve the application in its current form, citing the IGNYTE trial’s shortcomings.
Following the release of this information, Replimune‘s stock price experienced a dramatic decline of over 73% in intraday trading on July 22, 2025. This sharp drop underscores the severity of the situation for affected investors.
Faruqi & Faruqi is seeking to appoint a lead plaintiff for the class action. The lead plaintiff will be the investor with the largest financial stake in the case and will represent the interests of all class members. Investors who purchased Replimune securities between November 22, 2024, and July 21, 2025, are encouraged to contact the firm to learn more about their rights.
James (Josh) Wilson, a securities litigation partner at Faruqi & Faruqi, is leading the investigation. He encourages investors to reach out directly to discuss their options. The firm is also accepting information from whistleblowers, former employees, and others with relevant knowledge of Replimune‘s conduct.
The deadline for investors to seek the role of lead plaintiff in the class action is September 22, 2025. Faruqi & Faruqi has a history of representing investors in securities l
Related
